However, because of the limitations of CTC detection markers (e.g., EpCAM) and lower CTC detection sensitivity via conventional methods, the role of CTCs as therapeutic markers for adjuvant chemotherapy in stage II CRC and their utility for predicting cancer recurrence in LARC patients receiving NCRT remain controversial. The gene discussed is EPCAM; the disease is cancer.